智通财经APP获悉，近日，晶泰科技(02228)孵化企业默达生物(META Pharmaceuticals Inc.)宣布，其针对 炎症性肠病(IBD)开发的首个临床开发候选分子(PCC)MP-5342已确定，目前正积极准备新药临床试验 (IND)申请，预计最早于2026年下半年启动正式临床试验注册。MP-5342是晶泰科技赋能默达生物开发 的全球首款口服小分子乳酸脱氢酶(LDH)抑制剂。 随着晶泰科技参与发现和优化的创新药管线陆续进入临床阶段，公司将持续积累研发数据驱动AI算法 迭代升级，赋能更多合作伙伴加速源头创新突破，推动全球突破性疗法更快惠及患者，加速兑现人工智 能在生物医药领域的巨大社会价值与经济潜力。 关于默达生物 默达生物(META Pharmaceuticals Inc.)是一家专注于自身免疫疾病及代谢疾病药物研发的创新药物公司， 由AI制药先锋企业晶泰科技、Forcefield Ventures、IMO Ventures共同孵化，天图资本、雅亿资本、方圆 资本、新产业创投、德迅投资、博普资本参与投资。默达生物基于前沿的新兴生物学理论，通过调节细 胞新陈代谢的活力实现对免疫系统功能及其他生理系 ...

Group 1 - The core point of the article is that Jingtai Holdings (02228.HK) experienced a significant increase in stock price, rising over 4% in early trading [2] - As of the time of reporting, the stock price reached 11.8 HKD, reflecting a gain of 4.52% [2] - The trading volume for the stock was reported at 296 million HKD [2]

Group 1 - The core viewpoint of the article highlights that Jingtai Holdings (02228) has successfully delivered an automated workstation for formula stability testing to BASF, enhancing BASF's automation system across sample management, testing analysis, and data management [1] - The stock price of Jingtai Holdings increased by 4.52%, reaching HKD 11.8, with a trading volume of HKD 296 million [1] - The automated platform has been successfully delivered in high-value fields such as new drug development, chemical synthesis, and new material discovery [1] Group 2 - On February 5, Jingtai Holdings announced a project agreement and long-term strategic cooperation with Weisheng Pharmaceutical (02561) [1] - The collaboration aims to integrate Jingtai Holdings' AI and robotics drug development platform with Weisheng Pharmaceutical's expertise in the endocrine field, focusing on high clinical value indications and innovative targets [1] - This partnership seeks to advance the early discovery and clinical translation of innovative therapies in the endocrine treatment sector, targeting a market potential worth hundreds of billions [1]

Core Viewpoint - Crystal Tech Holdings (02228) has successfully delivered an automated workstation for formula stability testing to BASF, enhancing BASF's automation system across various high-value fields such as new drug development and chemical synthesis [1] Group 1: Company Developments - Crystal Tech Holdings' stock rose over 4%, reaching 11.8 HKD with a trading volume of 296 million HKD [1] - The automated workstation delivered to BASF supports a comprehensive automation system for sample management, testing analysis, and data management [1] Group 2: Strategic Partnerships - On February 5, Crystal Tech Holdings announced a project agreement and long-term strategic cooperation with Weisheng Pharmaceutical (02561) [1] - The collaboration aims to integrate Crystal Tech's AI and robotics drug development platform with Weisheng's expertise in the endocrine field, focusing on high clinical value indications and innovative targets [1] - This partnership seeks to advance the early discovery and clinical translation of innovative therapies in the endocrine treatment sector, targeting a market potential worth hundreds of billions [1]

Group 1 - The core achievement of the company is the successful delivery of an automated workstation for formulation stability testing to BASF, a global leader in the chemical industry, enhancing BASF's automated system for sample management, testing analysis, and data management [1] - This collaboration signifies a significant advancement in the company's intelligent autonomous laboratory solutions within the chemical automation sector, validating its technical strength and commercial delivery capabilities [1][2] - The company's modular standard platform and agile customization capabilities have been successfully implemented in high-value fields such as new drug development and chemical synthesis, ensuring efficient deployment and stable operation [2] Group 2 - The automated laboratory solutions have been adopted by various large enterprises and top research institutions, including international pharmaceutical companies and major universities, expanding the company's business boundaries from pharmaceutical research to large-scale chemical and new energy markets [3] - The company aims to deepen strategic collaboration with global industry leaders, accelerating the technological iteration of intelligent laboratories and providing core infrastructure for innovation in industrial research efficiency [3] - The integration of AI in research is positioning the company's automated laboratories as essential infrastructure for future AI-driven research, establishing a unique competitive barrier in the market [2]

此次合作的成功实施得益于本集团智能自主实验室独特的模块化标准平台与敏捷定制能力的深度融合。 该平台已在新药研发、化工合成、新材料发现等多个高价值领域实现成功交付，积累了深厚经验，其模 块化设计既能确保高效部署与稳定运行，又能为快速交付奠定基础。此次合作中，本集团能通过全球顶 尖技术标准的严苛验证，并实现近乎"零缺陷"的交付目标，不仅是对其机器人自动化实验技术先进性、 解决方案成熟度的验证，更是对其商业化能力的有力证明，进一步奠定了本集团在化学自动化领域的权 威地位。本集团的自主实验室不仅能实现实验操作的高度标准化与实验通量的显著提升，更能作为高效 生成高精度结构化数据的平台，持续、稳定地收集海量标准化实验数据，为研发领域专有AI模型的开 发与持续优化提供关键燃料。 随着AI在研发领域的深度渗透，能够自动化执行并规模化生成高质量数据的智能实验室，已成为未来 AI研发的核心基础设施，而本集团已在该领域占据先发和领先优势，构筑起独特的竞争壁垒：作为全 球稀缺的AI算法平台与大规模机器人实验深度集成的平台，本集团的自动化实验室持续获得顶级客户 的选择与背书，不断推进技术升级与经验沉淀，交付能力实现阶梯式跃升。 智通财 ...

Core Insights - The company has successfully delivered an automated formulation stability testing workstation to BASF, enhancing BASF's automated system for sample management, testing analysis, and data management [1] - This collaboration marks a significant advancement in the company's intelligent autonomous laboratory solutions within the chemical automation sector, validating its technical strength and commercial delivery capabilities [1][2] Group 1 - The successful implementation of this collaboration is attributed to the unique modular standard platform and agile customization capabilities of the company's intelligent autonomous laboratory [2] - The platform has achieved successful delivery in high-value areas such as new drug development, chemical synthesis, and new material discovery, accumulating substantial experience [2] - The company aims to establish a strong authority in chemical automation, evidenced by its ability to meet stringent global technology standards and achieve near "zero defects" in delivery [2] Group 2 - The company's automated laboratory solutions are currently serving various large enterprises and top research institutions, including international pharmaceutical companies and major universities [3] - The business model of "standardized platform + agile customization" is expanding from pharmaceutical research into the trillion-dollar markets of large chemicals and new energy [3] - The company plans to deepen strategic collaboration with global industry leaders to accelerate the technological iteration and experience accumulation of intelligent laboratories, driving the chemical research into a new era powered by AI and robotics [3]

本自願公告乃由晶泰控股有限公司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」） 作 出，以 知 會 股 東 及 潛 在 投 資 者 有 關 本 集 團 的 最 新 業 務 發 展。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 XtalPi Holdings Limited 晶泰控股有限公司 （於 開 曼 群 島 註 冊 成 立 之 有 限 公 司） （股 份 代 號：2228） 自願性公告 晶 泰 科 技 機 器 人 實 驗 室 落 地 巴 斯 夫， 全球技術領導力獲化工業頂級背書 本公司董事會（「董事會」）欣 然 宣 布，近 日，本 集 團 已 成 功 向 全 球 化 工 巨 頭 巴 斯 夫(BASF)交 付 了 一 種 配 方 穩 定 性 測 試 自 動 化 工 作 站，助 力 巴 斯 夫 構 建 起「樣 品 管 理－測 試 分 析－數 據 管 理」全 鏈 路 的 自 動 化 ...

致：香港交易及結算所有限公司 公司名稱: 晶泰控股有限公司 ("本公司"） 呈交日期: 2026年2月5日 I. 法定/註冊股本變動 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 第 1 頁 共 10 頁 v 1.2.0 FF301 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02228 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 100,000,000,000 | USD | | 0.00001 | USD | | 1,000,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 100,000,000,000 | USD ...

张玮航 国联民生证券医药分析师: 那个，我是今天的主持人。那个国联医生那个研究所的那个研究员张金阳，那个在线跟我 一起主持的还有我们这个研究员胡博、郑博，还有韦超，那个几位分析师老师在线。我在 开始这个，就是整个电话会之前，我可能就在前面要多说几句。那个整个 AI 赋能的这个 创新药的这个板块。其实是我们 2026 年整个年度策略的十大判断里面的一个非常重要的 一个分支，这个我们放到很重要的一个位置。在这里面，我们那个其实也很看好那个静态 这个公司的这个平台的价值。 其实包括我们在路演的过程当中，其实大家分歧比较大的，就是早期的时候，其实我们在 讨论的就是 AI 智能创校这个事到底靠谱到什么程度。后面，慢慢，其实大家已经讨论到 就是这个东西到底怎么给估值，那个维度，对吧？但我们一直跟大家讲，其实 AI 赋能这 个创新药这个方，这个方面，谁家这个平台和模型能力强，其实你从估值的角度是要去想 它的平台和模型的价值。所以，这个事我们就认为很重要。那如果这么这个事是重要的话 那从估值的角度来讲，应该用，从特别远期的角度往回看。 可能会看得更清晰一点。那么怎么证明平台和模型的价值大？其实就是在于说，我觉得就 是我们基于 ...